Over the past year, leaders around the globe have held their breath as the pandemic unfolded and drastic measures were tested, from safety mitigation and scientific developments to unprecedented fiscal stimulus. And now, as we emerge from the cloud of 2020, it is likely the current pandemic will soon pass to become an endemic. Even with this transition, the ... READ MORE >
Life Sciences
The life sciences sector comprises some of the middle market’s fastest-growing companies. Whether developing life-saving new drugs or robotic components for surgery, this vibrant sector is a hotbed of innovation.
Understanding the rapid spread of COVID-19 variants
As of March 12, more than 341 million doses of COVID-19 vaccines have been administered globally at a remarkable pace of 8.5 million doses a day, according to Bloomberg. Nearly a third of those vaccinations have occurred in the United States, where we have already administered more than 101 million doses and are giving another 2.3 million doses a day. ... READ MORE >
5 things to know in life sciences: Week of March 8
This week we look to make sense of COVID-19 variants. We also examine what appears to be heightened scrutiny on accelerated approvals for some treatments, gaps in the understanding of racial and ethnic representation in vaccine trials, tiny cancer-fighting robots and a new contract development and manufacturing organization facility coming to Texas. Each ... READ MORE >
5 things to know in life sciences: Week of March 1
In this week’s roundup we look at new data coming out of the United Kingdom and Israel on their COVID-19 vaccination programs’ results. The U.K. reported last week promising data on the efficacy of the Pfizer-BioNTech vaccine after just one dose. We also highlight improvements in public perception of the pharmaceutical industry, a new executive order on ... READ MORE >
5 things to know in life sciences: Week of Feb. 22
In this week’s roundup we look at two important developments in the ongoing response to the pandemic. The first is the likelihood that Johnson & Johnson’s vaccine could be approved under an emergency use authorization (EUA) as early as this weekend. The second is a major new effort by the U.S. government to expand genomic sequencing to track new COVID-19 ... READ MORE >
5 things to know in life sciences: Week of Feb. 15
In this week’s roundup we look at promising results in a clinical trial leveraging an existing diabetes drug for the treatment of obesity, a new and less invasive treatment for sleep apnea, and a new technology in cardiac catheters. We also examine the impact of the pandemic on oncology trials and the challenges of developing new treatments for Alzheimer’s ... READ MORE >
5 things to know in life sciences: Week of Feb. 8
In this week’s roundup, we look at the impact of new COVID-19 variants on existing vaccines for the disease; South Africa made the difficult decision to stop using its most readily available vaccine after it showed limited effectiveness against the variant most common there. This is an important reminder that getting the first vaccines approved was a ... READ MORE >
CHART OF THE DAY: How COVID-19 vaccines compare on cold storage requirements
About 100 million people tuned in to the watch the Super Bowl on Sunday – that’s almost four times the number of Americans who have received their first jab of a COVID-19 vaccine. While the world’s largest vaccination effort is not going 100% according to plan, the Centers for Disease Control and Prevention’s vaccination tracker shows that of the 59.3 ... READ MORE >
5 things to know in life sciences: Week of Feb. 1
In this week’s roundup, we examine why more drug manufacturers are not stepping in to help produce mRNA-based COVID-19 vaccines. While some may think drug manufacturing facilities should be able to easily pivot to produce these vaccines, the reality is much more complicated. We also look at investment patterns in gene therapy companies, a new Food and ... READ MORE >
5 things to know in life sciences: Week of Jan. 25
This week’s roundup includes several reads about a crucial but often unnoticed shift in the life sciences ecosystem—the interplay between the digital future of life science, the development of next generation therapeutics, and the promise of personalized medicine. The drop in cost and increase in accuracy of genome sequencing has not only led to the rapid ... READ MORE >